Helius Medical Technologies - Home


Call us: +1 877-564-0008


Stock Quote - HSDT

*Delayed quote courtesy of Google.

Helius Medical Technologies Inventors Granted US Patent No. 9,020,612 “Non-Invasive Neuromodulation (NINM) For Rehabilitation of Brain Function”

NEWTOWN, PA – April 14, 2015 – Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) (“Helius”, or the “Company”) announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS™) device and the associated therapeutic modality. U.S. Patent No. 9,020,612 “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function”, issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.

Cranial Nerve – Non Invasive Neuromodulation (CN-NINM) therapy is believed to facilitate the brain’s ability to rehabilitate and compensate for symptoms caused by disease or trauma. The PoNS™ device and the CN-NINM therapy is currently being studied in the United States for the treatment of chronic balance disorders caused by mild-moderate Traumatic Brain Injury (“TBI”) and in Canada for chronic balance and gait disorders caused by Multiple Sclerosis.

“Our growing patent portfolio continues to protect our vision to revolutionize the treatment of brain injury symptoms. Protecting our unique technology and therapeutic modality is fundamental for our growth as a company and our ability to properly and aggressively reshape this space,” said Philippe Deschamps, Chief Executive Officer of Helius.

This USPTO issuance is the third patent Helius has received related to the PoNS™ device and the associated therapeutic modality.  The first PoNS™ patent, US Patent No. 8,849,407, was issued on September 30, 2014.  The second PoNS™ patent, US Patent No. 8,909,345 was issued on December 9, 2014.  The Company also filed more than two dozen patent applications to protect the valuable technical features and ornamental design elements of the PoNS™ device.  Helius expects to file additional patent applications to protect its technology, designs and therapeutic methods as they evolve.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. The company’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. For more information, please visit www.heliusmedical.com.

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

# # #


US Investor Relations:

                        Todd James

646 378 2926             


Canadian Investor Relations:



Corporate Contact:
Phil Deschamps



Media Contact:

Becky Kern